Finland
StemSight is a biotechnology startup based in Finland, founded in 2021. The company's slogan, "Curing blindness with regenerative cell therapies," encapsulates its mission to develop off-the-shelf regenerative cell therapies for corneal blindness. StemSight's innovative approach involves the combination of iPS-derived cells with functional biomaterials, enabling faster tissue regeneration, safer cell therapies, and easier cell delivery.
In September 2021, StemSight achieved a significant milestone with a €500.00K Seed Round investment, demonstrating early confidence in its groundbreaking technology. The investment came from Avohoidon Tutkimussäätiö and Voima Ventures, prominent investors in the biotechnology and healthcare sectors.
StemSight's focus on addressing corneal blindness through regenerative cell therapies positions the company at the forefront of innovative medical solutions. With its strong foundation and recent investment, StemSight is poised to make substantial contributions to the field of biotechnology and, more importantly, to the lives of individuals suffering from corneal blindness.
